Genmab — November 2025

[lahn1]

Nice story EL

[JKY_VH]

Genmab/Kepler: Dækning genoptages med neutral anbefaling og kursmål på 2100 kr.

[bibob]

Tak @jky. Så er der plads til mere og en købsanbefaling. D

[JKY_VH]

Lige præcis bibob

[E_L]

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab https://www.prnewswire.com/news-releases/merus-and-halozyme-enter-global-collaboration-and-license-agreement-to-develop-subcutaneous-formulation-of-petosemtamab-302616859.html

[Sukkeralf]

Nice - and this time no JNJ to steal all the money

[E_L]

Tahi Ahmadi spoke about life cycle management on the Q3 call when asked about SC for Peto, so I sort of thought they would wait a bit with it... But speeding things up makes sense with strong competition

[Sukkeralf]

Just a moment...

(www.fiercebiotech.com)

[LP90]

Godmorgen

[Helge_LarsenPI-redaktør]

Godmorgen

[bibob]

God morgen.

[JKY_VH]

Nogen har set lyset "Genmab/Rothschild: Hæver kursmålet til 3060 kr. fra 2860 kr.
Genmab har fået hævet sit kursmål til 3060 kr. fra 2860 kr. af finanshuset Rothschild & Co. Redburn.

Den positive anbefaling "køb" bliver i samme ombæring gentaget, viser data fra Bloomberg News.

Genmab-aktien lukkede fredag med et fald på 0,6 pct. i 1953,50 kr., hvilket giver et potentiale på 56,7 pct. i forhold til Rothschild & Co. Redburns nye kursmål.

.\˙ MarketWire"

[bibob]

@JKY. Ja det må være julelyset der er blevet tændt. Og stjernen på toppen.

[JKY_VH]

synes nok at lyset blev slukket lidt for hurtigt:-)

[bibob]

Følger bare markedet.

[E_L]

TALVEY▼ (talquetamab) receives positive NICE recommendation in Final Draft Guidance for treating relapsed and refractory multiple myeloma after three or more lines of treatment https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/talvey-talquetamab-receives-positive-nice-recommendation-in-final-draft-guidance-for-treating-relapsed-and-refractory-multiple-myeloma

[E_L]

Funded by Pfizer and Genmab, this project addresses the urgent barriers faced by patients and clinicians navigating recurrent or metastatic cervical cancer. https://kcmsociety.org/

[E_L]

Next-gen treatment keeps myeloma at bay for a year / talquetamab UK https://www.myeloma.org.uk/news/next-gen-treatment-keeps-myeloma-at-bay-for-a-year/

[E_L]

The Sub-Q Therapy That Cut Hours Off Treatment Time https://www.curetoday.com/view/the-sub-q-therapy-that-cut-hours-off-treatment-time

[E_L]

also in reference to yesterdays announcement on Subcutaneous Formulation of Petosemtamab, even ethically you would have to wonder if you could delay SC for life cycle management...